Skip to main content
SpringerLink
Log in

In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Thein vitro activities of taxol and taxotere in comparison with cisplatin and doxorubicin were assessed in 30 primary tumor cultures from human breast cancers. Both taxanes were much more potent than cisplatin and doxorubicin. Taxotere was 3.1; 296, and 9.6-fold more cytotoxic than taxol, cisplatin, and doxorubicin respectively. The cytotoxic activity observed in our experiments confirms the potential clinical relevance of the two taxanes in the management of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assemblyin vitro by taxol. Nature 22: 665–667, 1979

    Google Scholar 

  2. Wani MC, Taylor HL, Wall ME: Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent fromTaxus brevifolia. Am Chem Soc 93: 2325–2327, 1971

    Google Scholar 

  3. National Cancer Institute Clinical Brochure: Taxol (NSC 125973). Division of Cancer Treatment, NCI, Bethesda, MD 1991

    Google Scholar 

  4. Denis JN, Greene AE: A highly efficient approach to natural taxol. J Am Chem Soc 110: 5917–5919, 1988

    Google Scholar 

  5. Mangatal L, Adeline MT, Guenard D: Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron 45: 4177–4190, 1989

    Google Scholar 

  6. Ringel I, Horwitz SP: Studies with RP56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288–291, 1991

    Google Scholar 

  7. Bissery MC, Guenard D, Gueritte-Voegelein F: Experimental antitumor activity of taxotere (RP56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845–4852, 1991

    Google Scholar 

  8. Stampfer MR, Hallowes RC, Hackett AJ: Growth of normal human mammary cells in culture.In Vitro Cell Dev Biol 16: 415–425, 1980

    Google Scholar 

  9. Smith HS, Lan S, Ceriani R, Hackett AJ, Stampfer MR: Clonal proliferation of cultured nonmalignant and malignant human breast epithelia. Cancer Res 41: 4637–4643, 1981

    Google Scholar 

  10. Stampfer MR, Hackett AJ, Hancock MC, Leung JP, Edgington TS, Smith HS: Growth of human mammary epithelium in culture and expression of tumor specific properties. Cold Spring Harbor Symposium on Cellular Proliferation 9: 819–929, 1982

    Google Scholar 

  11. E.O.R.T.C. Breast Cancer Cooperative Group: Revision of the standards for the assessment of the hormone receptors in human breast cancer. Eur J Cancer 16: 1513–1515, 1980

    Google Scholar 

  12. Silvestrini R, Daidone MG, Valentinis B, Ferraris C, DiRe E, Raspagliesi F, Landoni F, Scarfone G, Bolis G: Potential of cell kinetics in the managment of patients with ovarian cancers. Eur J Cancer 28: 386–390, 1992

    Google Scholar 

  13. Amadori D, Bonaguri C, Nanni O, Gentilini P, Lundi N, Zoli W, Riccobon A, Vio A, Magni E, Saragoni A: Cell kinetics and hormonal features in relation to pathological stage in breast cancer. Breast Cancer Res Treat 18: 19–25, 1991

    Google Scholar 

  14. Smith HS, Lippman ME, Hiller AJ, Stampfer MR, Hackett AJ: Response to doxorubicin of cultured normal and malignant mammary epithelial cells. J Natl Cancer Inst 74: 341–348, 1985

    Google Scholar 

  15. Smith HS, Zoli W, Lippman ME, Howlett A, Volpi A, Amadori D: Development and application of a highly efficientin vitro assay for predicting the chemosensitivity of human breast cancers. In: Amadori D, Ravaioli A, Ridolfi R (eds) Strategies in cancer medical therapy: biological bases and clinical implication, 1989

  16. Smith HS, Zoli W, Volpi A, Hiller A, Lippman ME, Swain S, Nayall B, Dollbaum C, Hackett AJ, Amadori D: Preliminary correlations of clinical outcome within vitro chemosensitivity of second passage human breast cancer cells. Cancer Res 50: 2943–2948, 1990

    Google Scholar 

  17. Zoli W, Volpi A, Bonaguri C, Riccobon A, Savini S, Brizio R, Saragoni A, Medri L, Marra GA, Amadori D: An efficient method for culturing human breast cancer to evaluate antiblastic drug activityin vitro: experience on 136 primary cancers and on 116 recurrences. Breast Cancer Res Treat 17: 231–238, 1990

    Google Scholar 

  18. Alberts DS, Chen HS: Tabular summary of pharmacokinetic parameters relevant toin vitro drug testing. In: Salmon S (ed) Cloning of human tumor stem cells. Liss, New York, 1980, pp 351–359

    Google Scholar 

  19. Wiernik PII, Schwartz EL, Einzing A, Strauman II, Lipton RB, Dutcher JP: Phase I trial of taxol in patients with advanced malignancies. Cancer Treat Rep 71: 1171–1177, 1987

    Google Scholar 

  20. Koechli OR, Sevin BU, Perras JP, Chou TC, Angioli R, Steren A, Untch M, Averette HE: Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell Viability Assay. Breast Cancer Res Treat 28: 21–27, 1993

    Google Scholar 

  21. Irvin RJ, Burris H, Eckardt J, Rodriguez G, Weiss G, Koeller J, Von Hoff DD, Kuhn JG: Pharmacokinetics of a 6 hr Taxotere infusion (RP56976, NSC628503). Proc Am Soc Clin Oncol 11: 108a, 1992

    Google Scholar 

  22. Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D Jr, Jaiyesimi I, Vreeland F, Bayssas MMG, Raber MN: Phase I trial of taxotere: five-day schedule. JNCI 84: 1781–1788, 1992

    Google Scholar 

  23. Silvestrini R, Zaffaroni N, Orlandi L, Saro O:In vitro cytotoxic activity of taxol and taxotere on primary cultures and established cell lines of human ovarian cancer. Stem Cells 11: 528–535, 1993

    Google Scholar 

  24. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P: Relationship between the structure of taxol analogues and their antimitotic activity. J Med Chem 34: 992–998, 1991

    Google Scholar 

  25. Vogel M, Hilsenbeck SG, Depenbrock H, Danhauser-Riedl S, Block T, Nekarda H, Fellbaum CH, Aapro MS, Bissery MC, Rastetter J, Hanauske AR: Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumor cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer (in press)

  26. Kelland LR, Abel G: Comparativein vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30: 444–450, 1992

    Google Scholar 

  27. Eisenhauer E, Lofters W, Norris B, Muldal A, Letendre F, Vandenburg T, Verma S: Phase II study of taxotere as first line chemotherapy for metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. (Abstract) Proc ASCO 12: 64, 1993

    Google Scholar 

  28. Seidman AD, Hudis C, Crown JPA, Balmaceda C, Lebwohl D, Currie V, Gilewski T, Hakes T, Robles M, Klem K, Lepore J, Norton L: Phase II evaluation of taxotere (RP56976, NSC628503) as initial chemotherapy for metastatic breast cancer. (Abstract) Proc ASCO 12: 63, 1993

    Google Scholar 

  29. Fumoleau P, Chevallier B, Kerbrat T, Dieras V, De Bail N, Bayssas M, Van Glabbeke M: First line chemotherapy with taxotere in advanced breast cancer: A phase II study of the EORTC Clinical Screening Group. (Abstract) Proc ASCO 12: 56, 1993

    Google Scholar 

  30. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG: Taxol: The first of taxanes, an important new class of antitumor agents. Semin Oncol 19: 646–662, 1992

    Google Scholar 

  31. Holmes FA, Walters RS, Theriault RL: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797–18005, 1991

    Google Scholar 

  32. Weiss RB: The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 19: 670–686, 1992

    Google Scholar 

  33. Bisset D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB, Kerr DJ: Phase I pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53: 523–527, 1993

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, G.B. Morgagni-L. Pierantoni Hospital, U.S.L. 38, Viale Forlanini, 47100, Forli, Italy

    Wainer Zoli, Giovanni Luca Frassineti, Carlo Milandri & Dino Amadori

  2. Istituto Oncologico Romagnolo, Forli, Italy

    Alberto Flamigni, Paola Bajorko & Franca De Paola

  3. Interdepartmental Center for Research on Cancer, University of Bologna, Italy

    Anna Gasperi-Campani

  4. Department of Experimental Pathology, University of Bologna, Italy

    Anna Gasperi-Campani

Authors
  1. Wainer Zoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Flamigni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giovanni Luca Frassineti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paola Bajorko
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Franca De Paola
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carlo Milandri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dino Amadori
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anna Gasperi-Campani
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zoli, W., Flamigni, A., Frassineti, G.L. et al. In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers. Breast Cancer Res Tr 34, 63–69 (1995). https://doi.org/10.1007/BF00666492

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00666492

Key words

Search

Navigation